Insider sale details
Disc Medicine (NASDAQ: IRON) Chief Medical Officer William Jacob Savage sold a total of 5,731 shares of the company’s common stock on April 13, 2026, according to a Form 4 filing. The sales were executed pursuant to a Rule 10b5-1 trading arrangement and produced aggregate proceeds of approximately $380,448.
The disposition was carried out in two separate transactions. The first tranche comprised 3,531 shares at a weighted average price of $66.1209, with individual trade prices ranging from $65.50 to $66.39. The second tranche covered 2,200 shares at a weighted average price of $66.8073, with per-share prices between $66.57 and $67.00.
Post-transaction ownership and market context
After these sales, Savage’s direct ownership in Disc Medicine stands at 79,480 shares. The company’s stock has appreciated by more than 70% over the prior year. At present, the shares trade above InvestingPro’s Fair Value and are listed on its Most Overvalued list. Disc Medicine’s market capitalization is reported at $2.68 billion.
Clinical program and enrollment
On the clinical front, Disc Medicine has completed enrollment for its Phase 3 APOLLO trial testing bitopertin in erythropoietic protoporphyria (EPP). Enrollment expanded to 183 participants after strong demand, exceeding the originally planned cohort of 150 subjects.
Regulatory setback and workforce changes
The company announced a restructuring and headcount reduction following a Complete Response Letter from the U.S. Food and Drug Administration related to the New Drug Application for bitopertin. The plan calls for cutting roughly 20% of the workforce, with reductions concentrated in commercial functions and supporting roles. The company expects the reduction and restructuring effort to be completed in the second quarter of 2026.
Analyst reactions
Analysts have updated their models in response to the regulatory news and competitive landscape. Stifel reiterated a Buy rating for Disc Medicine, maintaining a price target of $111 following the presentation of results from a competing drug’s trial. However, Stifel also adjusted its price target to $110 from $125 as a result of the FDA setback. Cantor Fitzgerald lowered its price target to $125 from $153 while keeping an Overweight rating.
What this means for investors
The insider sale, ongoing clinical progress with expanded trial enrollment, the FDA’s Complete Response Letter, and the accompanying workforce reductions combine to create a complex operational picture for Disc Medicine. The company’s recent stock appreciation and valuation placement on InvestingPro’s Most Overvalued list sit alongside continued clinical development and analyst recalibrations of price targets.
Investors tracking IRON will see both near-term operational adjustments and longer-term clinical readouts as factors that could influence the company’s trajectory.